Unlock instant, AI-driven research and patent intelligence for your innovation.

Novel sulfated oligosaccharide derivatives

一种化合物、通式化合物的技术,应用在新的硫酸化寡糖衍生物领域,能够解决没有表现出抗-IIa活性等问题

Inactive Publication Date: 2015-06-03
PROGEN PHARMA LTD
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, PI-88 does not interact with ATIII and therefore does not exhibit anti-Xa or AT III-mediated anti-IIa activity 12,13

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel sulfated oligosaccharide derivatives
  • Novel sulfated oligosaccharide derivatives
  • Novel sulfated oligosaccharide derivatives

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0083] Example 1: Dodecyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl-(1→3)-2,4,6-tri-O-acetyl -Α-D-Mannopyranosyl-(1→3)-2,4,6-tris-O-acetyl-α-D-Mannopyranosyl-(1→3)-2,4 ,6-Tri-O-acetyl-α-D-mannopyranosyl-(1→2)-3,4,6-tri-O-acetyl-α-D-mannopyranoside(2)

[0084] To Trichloroacetate Imidate 1 28 (0.469g, 0.285mmol) in DCM (15mL) was added 1-dodecanol (0.849mmol, 3 equivalents) and MS (50 mg). The mixture was stirred at -20°C for 20 minutes. Add TMSOTf (103μL, 0.57mmol, 2eq) and use Et 3 The mixture was stirred at -20°C for 50 minutes before being quenched with N (38 μL, 0.285 mmol, 1 equivalent). After warming to room temperature, the mixture was filtered and the solids were washed with DCM. The combined filtrate and washing liquid were evaporated on silica gel and passed through column chromatography (silica 2×20cm, CHCl 3 , CHCl 3 -Methanol (99:1 to 98:2 gradient elution) was purified to obtain glycoside 2 in the form of a colorless gum. A two-part fraction BnNHAc (76 mg, 2:Bn...

Embodiment 2

[0089] Example 2: 12-azido-1-dodecanol

[0090] Treat 12-bromo-1 with sodium azide (121 mg, 1.855 mmol, 2 equivalents), tetrabutylammonium iodide (17 mg, 0.0464 mmol, 0.05 equivalents) and saturated aqueous sodium bicarbonate (0.9 mL) in the following order -A mixture of dodecanol (246 mg, 0.927 mmol) in tert-butanol (1.8 mL, 0.5M). The mixture was stirred at room temperature for 4 days. The mixture was filtered through a short column of Celite, and the filter cake was rinsed with ethyl acetate (20 mL). The combined filtrate and washing liquid were evaporated on silica gel, and purified by flash column chromatography (2.5×18cm, hexane-ethyl acetate 6:1, 4:1 to 2:1 gradient elution) to obtain colorless Oily 12-azido-1-dodecanol (193 mg, 92%). 1 H NMR(CDCl 3 , 400MHz): 3.62(t, 2H, J=7.0, OCH 2 ), 3.24(t, 2H, J=7.0, NCH 2 ), 1.61-1.51 (m, 4H), 1.35-1.25 (m, 16H).

[0091] 12-azidododecyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl-(1→3)-2,4,6-tri-O- Acetyl-α-D-Mannopyranosyl-(1→3)-2...

Embodiment 3

[0097] Example 3: 12-(4-naphthyl-1-yl-[1,2,3]triazol-1-yl)dodecyl 2,3,4,6-tetra-O-acetyl-α -D-Mannopyranosyl-(1→3)-2,4,6-tri-O-acetyl-α-D-Mannopyranosyl-(1→3)-2,4,6- Tri-O-Acetyl-α-D-Mannopyranosyl-(1→3)-2,4,6-Tri-O-acetyl-α-D-Mannopyranosyl-(1→2 )-3,4,6-Tri-O-acetyl-α-D-mannopyranoside (9)

[0098] Load azide 5 (86mg, 50.3μmol), tert-butanol (100μL, 0.4M), 1-ethynylnaphthalene (83μmol, 2 equivalents), copper sulfate solution (0.3 in water) into a 1mL HPLC sample bottle in the following order M, 14 μL, 4.2 μmol, 10 mol%) and sodium ascorbate solution (1M, in water, 12.4 μL, 12.4 μmol, 30 mol%). The mixture was stirred at room temperature for 11 days. Then the mixture was evaporated on silica gel and flash column chromatography (1×18cm, eluted with a gradient of hexane-ethyl acetate 6:1, 4:1, 2:1, 1:1, 1:2 to 1:3 ) It was purified to obtain a colorless colloid naphthyltriazole 9 (24.2 mg, 26%). 1 H NMR(CDCl 3 , 400MHz) δ 8.38-8.33 (m, 1H), 7.92-7.86 (m, 2H), 7.80 (s, 1H, triaz...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and / or antithrombotic treatment of a mammalian subject.

Description

[0001] This divisional application is based on the divisional application of the original Chinese patent application with the application number 200880116727.9, the filing date being October 16, 2008, and the invention title "New Sulfated Oligosaccharide Derivatives". Technical field [0002] The invention described herein relates to compounds having activity as inhibitors of heparan sulfate-binding proteins including heparanase. In particular, the present invention relates to sulfated oligosaccharide derivatives. Although the scope of the present invention is not necessarily limited thereto, in particular, the present invention relates to polysulfated oligosaccharides modified with specific, highly lipophilic groups. The present invention also relates to a method for preparing the compound, a composition containing the compound, and the compound and the composition are used in mammalian subjects for anti-angiogenesis, anti-metastasis, anti-inflammatory, anti-microbial, anti-coagu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7028A61K31/7056A61K31/704A61K31/7016A61K31/7024A61K31/706A61P35/00A61P35/04
CPCC07H3/04C07H3/06C07H5/02C07H5/04C07H5/06C07H11/00C07H15/04C07H15/207C07H15/24C07H15/26C07H17/02C07J17/005C07J41/0088C07J41/0094A61P29/00A61P31/00A61P31/04A61P31/12A61P35/00A61P3/06A61P35/04A61P7/02A61P9/00C07J31/006C07J43/003
Inventor V·费尔罗T·卡洛丽刘立功P·N·汉德雷K·D·约翰斯通N·韦默E·T·哈蒙德
Owner PROGEN PHARMA LTD